PUMA Biotechnology officer sells 8,460 shares

PUMA Biotechnology officer Douglas M. Hunt reported an open-market sale of company stock.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PUMA Biotechnology officer Douglas M. Hunt reported an open-market sale of company stock. On the reported date, he sold 8,460 shares of PUMA Biotechnology common stock at an average price of $8.263 per share. After this transaction, he directly holds 196,841 shares of common stock. The filing notes that the sale occurred under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020, indicating the trade was executed pursuant to a pre-arranged trading plan.

Insider Trade Summary 10b5-1

Net Seller: 8,460 shares

Net Sell 1 txn

Insider HUNT DOUGLAS M

Role See Remarks

Sold 8,460 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,460	$8.263	$70K

Holdings After Transaction: Common Stock — 196,841 shares (Direct)

Footnotes (1)

F1. Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Key Figures

Shares sold: 8,460 shares Sale price per share: $8.263 per share Shares held after transaction: 196,841 shares +1 more

4 metrics

Shares sold 8,460 shares Open-market sale of common stock

Sale price per share $8.263 per share Average transaction price for the sale

Shares held after transaction 196,841 shares Direct ownership following the sale

Rule 10b5-1(c) plan adoption date December 14, 2020 Adoption of sell-to-cover trading program

Key Terms

Rule 10b5-1(c), sell to cover program, open-market sale, Form 4

4 terms

Rule 10b5-1(c) regulatory

"Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

sell to cover program financial

"Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PUMA Biotechnology (PBYI) report for Douglas M. Hunt?

PUMA Biotechnology reported that officer Douglas M. Hunt executed an open-market sale of company stock. He sold 8,460 shares of common stock as disclosed in a Form 4 insider trading report filed with regulators.

How many PBYI shares did Douglas M. Hunt sell and at what price?

Douglas M. Hunt sold 8,460 shares of PUMA Biotechnology common stock at an average price of $8.263 per share. This transaction was reported as an open-market sale in the Form 4 filing.

How many PUMA Biotechnology (PBYI) shares does Douglas M. Hunt hold after the sale?

Following the reported transaction, Douglas M. Hunt directly holds 196,841 shares of PUMA Biotechnology common stock. This post-transaction ownership figure is disclosed in the Form 4 as his remaining direct holdings.

Was Douglas M. Hunt’s PBYI stock sale under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnote states the sale occurred under a Rule 10b5-1(c) sell-to-cover program adopted on December 14, 2020. This indicates the trade was executed pursuant to a pre-arranged trading plan.

What type of transaction code is shown for Douglas M. Hunt’s PBYI trade?

The transaction is coded as “S,” indicating a sale in an open market or private transaction. The Form 4 also labels it as an open-market sale of common stock by Douglas M. Hunt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/08/2026 - 08:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUNT DOUGLAS M

(Last)

(First)

(Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES

CALIFORNIA

90024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/06/2026		S⁽¹⁾		8,460	D	$8.263	196,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020.

Remarks:

The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.

	/s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR